Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Medexus Pharmaceuticals's EV-to-OCF or its related term are showing as below:
TSX:MDP'
s EV-to-OCF Range Over the Past 10 Years
Min: -604.71 Med: -4.66 Max: 115.11
Current: 7
During the past 13 years, the highest EV-to-OCF of Medexus Pharmaceuticals was 115.11. The lowest was -604.71. And the median was -4.66.
TSX:MDP's EV-to-OCF is ranked better than 59.82% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.825
vs TSX:MDP: 7.00
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medexus Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Medexus Pharmaceuticals's share price for today is C$4.99.
Medexus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.097.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medexus Pharmaceuticals EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Medexus Pharmaceuticals's EV-to-OCF falls into.
Medexus Pharmaceuticals's current Enterprise Value is C$180.1 Mil.
Medexus Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$26.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals (TSX:MDP) has a EV-to-OCF of 6.93 as of Aug. 05, 2026. According to the industry distribution chart, Medexus Pharmaceuticals ranks #405 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 40.2%.
Is Medexus Pharmaceuticals' EV-to-OCF too high?
Medexus Pharmaceuticals' current EV-to-OCF is 6.93. The Drug Manufacturers industry median EV-to-OCF is 10.83. Medexus Pharmaceuticals' value of 6.93 is 36% below this industry median. Based on the distribution chart, Medexus Pharmaceuticals ranks #405 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Medexus Pharmaceuticals has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medexus Pharmaceuticals ranks #405 out of 1008 companies for EV-to-OCF. This puts Medexus Pharmaceuticals in the upper half of its industry. The industry median EV-to-OCF is 10.83. Medexus Pharmaceuticals' value of 6.93 is 36% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.83, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medexus Pharmaceuticals's current EV-to-OCF of 6.93 is 36% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current EV-to-OCF is 6.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (TSX:MDP) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.87, compared to a current price of C$4.99 — trading 166.8% above its estimated fair value. The current EV-to-OCF is 6.93 and 36% below the Drug Manufacturers industry median of 10.83. Medexus Pharmaceuticals' overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Medexus Pharmaceuticals (TSX:MDP), the current EV-to-OCF is 6.93 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medexus Pharmaceuticals (TSX:MDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued.
The current stock price of C$4.99 is trading 166.8% above its estimated GF Value™ of C$1.87.
GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for TSX:MDP:
EV-to-OCF: 6.93
GF Value™: C$1.87 vs. price of C$4.99 (166.8% above fair value)
Industry Position: 36% below the Drug Manufacturers median (#405 of 1008)
No single metric tells the full story. See the TSX:MDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
52GF Score
Get the complete analysis for TSX:MDP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:MDP has been successfully added to your 
